PMID

Data

Article Title

Organization

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

Merck

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.

Merck

The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics.

Merck

Investigation of piperazine benzamides as humanß

Merck

Novel reversible methionine aminopeptidase-2 (MetAP-2) inhibitors based on purine and related bicyclic templates.

Merck

Discovery of novel BTK inhibitors with carboxylic acids.

Merck

Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.

Merck

Discovery of phenyl acetamides as potent and selective GPR119 agonists.

Merck

p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.

Merck

MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.

Merck

Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.

Merck

Design, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists.

Merck

Discovery of Chromane Propionic Acid Analogues as Selective Agonists of GPR120 with

Merck

Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.

Merck

Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.

Merck

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

Merck

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.

Merck

Discovery of novel 7-azaindoles as PDK1 inhibitors.

Merck

Stacking with No Planarity?

Merck

Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors.

Merck

Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.

Merck

Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.

Merck

Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.

Merck

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Merck

Structure-based optimization of non-peptidic Cathepsin D inhibitors.

Merck

Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasms.

Merck

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Merck

The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization.

Merck

(E)-Alkenes as replacements of amide bonds: development of novel and potent acyclic CGRP receptor antagonists.

Merck

Fragment-based discovery of focal adhesion kinase inhibitors.

Merck

Evaluation of selective inhibitors of 11ß-HSD1 for the treatment of hypertension.

Merck

Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.

Merck

The discovery of highly potent CGRP receptor antagonists.

Merck

Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Merck

Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors.

Merck

Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.

Merck

Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.

Merck

An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.

Merck

Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.

Merck

3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of alpha5-containing GABAA receptors.

Merck

Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT(1A) and 5-HT re-uptake ligands.

Merck

Selective alpha-1a adrenergic receptor antagonists. Effects of pharmacophore regio- and stereochemistry on potency and selectivity.

Merck

Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ETA selective antagonist.

Merck

The discovery of potent antagonists of NPBWR1 (GPR7).

Merck

Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.

Merck

Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii.

Merck

Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.

Merck

Design of potent and selective GPR119 agonists for type II diabetes.

Merck

Substituted phenyl triazoles as selective inhibitors of 11 β-Hydroxysteroid Dehydrogenase Type 1.

Merck

Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.

Merck

The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead.

Merck

Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.

Merck

Anthranilic acid replacements in a niacin receptor agonist.

Merck

4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity.

Merck

Identification of potent, highly constrained CGRP receptor antagonists.

Merck

Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.

Merck

Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3).

Merck

Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.

Merck

Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening.

Merck

Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.

Merck

Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors.

Merck

Potent benzimidazolone-based CGRP receptor antagonists.

Merck

Bradykinin B1 receptor antagonists: an alpha-hydroxy amide with an improved metabolism profile.

Merck

2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.

Merck

Melanocortin subtype 4 receptor agonists: structure-activity relationships about the 4-alkyl piperidine core.

Merck

The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine.

Merck

Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series.

Merck

Potent bradykinin B1 receptor antagonists: 4-substituted phenyl cyclohexanes.

Merck

Identification of potent agonists of photoreceptor-specific nuclear receptor (NR2E3) and preparation of a radioligand.

Merck

Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity.

Merck

Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor.

Merck

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.

Merck

Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (?5i).

Merck

Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity.

Merck

Optimization and Mechanistic Investigations of Novel Allosteric Activators of PKG1?.

Merck

p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones.

Merck

Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.

Merck

Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology.

Merck

Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.

Merck

Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors.

Merck

The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.

Merck

Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.

Merck

Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridine series.

Merck

Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors.

Merck

Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis.

Merck

Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.

Merck

Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.

Merck

Potent and selective proline derived dipeptidyl peptidase IV inhibitors.

Merck

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.

Merck

Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.

Merck

Indolebutylamines as selective 5-HT(1A) agonists.

Merck

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Na

Merck

Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.

Merck

Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors.

Merck

Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.

Merck

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.

Merck

Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.

Merck

Discovery of

Merck

Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.

Merck

Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.

Merck

Discovery of the First Non-cGMP Mimetic Small Molecule Activators of cGMP-Dependent Protein Kinase 1 ? (PKG1?).

Merck

Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists.

Merck

Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.

Merck

Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3K? Immunomodulators.

Merck

Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors.

Merck

Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay.

Merck

4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.

Merck

Discovery of a new series of PI3K-? inhibitors from Virtual Screening.

Merck

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

Merck

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.

Merck

A general synthesis of 1-aryl carbamoyl-2-alkyl-4-aryl substituted semicarbazides as nonbasic factor Xa inhibitors.

Merck

SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors.

Merck

Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.

Merck

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold.

Merck

The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.

Merck

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.

Merck

Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.

Merck

Identification of Potent Reverse Indazole Inhibitors for HPK1.

Merck

Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen.

Merck

Discovery of Arylsulfonamide Na

Merck

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

Merck

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.

Merck

Biochemical, cellular and structural characterization of novel and selective ERK3 inhibitors.

Merck

Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7).

Merck

Carbamate and

Merck

Synthesis of HDAC Inhibitor Libraries via Microscale Workflow.

Merck

Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores.

Merck

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.

Merck

Optimization of Versatile Oxindoles as Selective PI3K? Inhibitors.

Merck

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.

Merck

Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir.

Merck

Generation of Leads for ?-Secretase Modulation.

Merck

Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B.

Merck

Cyclic imides as potent and selective alpha-1A adrenergic receptor antagonists.

Merck

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.

Merck

Discovery of hydroxy pyrimidine Factor IXa inhibitors.

Merck

Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.

Merck

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.

Merck

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).

Merck

Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors.

Merck

Discovery of 4-arylquinoline-2-carboxamides, highly potent and selective class of mGluR2 negative allosteric modulators: From HTS to activity in animal models.

Merck

Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy.

Merck

Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1).

Merck

Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.

Merck

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.

Merck

Phenylacetamides as selective alpha-1A adrenergic receptor antagonists.

Merck

Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.

Merck

Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.

Merck

5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.

Merck

Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy.

Merck

Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC).

Merck

Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.

Merck

Design of selective PI3K? inhibitors using an iterative scaffold-hopping workflow.

Merck

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING.

Merck

Benzofuro[3,2-b]pyridines as mixed ET(A)/ET(B) and selective ET(B) endothelin receptor antagonists.

Merck

4-Oxospiro[benzopyran-2,4'-piperidines] as selective alpha 1a-adrenergic receptor antagonists.

Merck

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

Merck

Design and synthesis of N-alkylated saccharins as selective alpha-1a adrenergic receptor antagonists.

Merck

Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.

Merck

Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.

Merck

Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization.

Merck

4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist.

Merck

Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as ROR??t Allosteric Inhibitors for Autoimmune Diseases

Merck

Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.

Merck

Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety.

Merck

Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase.

Merck

Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.

Merck

Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase.

Merck

Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Merck

Bicyclic acylguanidine Na+/H+ antiporter inhibitors.

Merck

(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors.

Merck

Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists.

Merck

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.

Merck

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

Merck

Identification of second-generation P2X3 antagonists for treatment of pain.

Merck

Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.

Merck

Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.

Merck

Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.

Merck

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

Merck

MK-7622: A First-in-Class M

Merck

The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.

Merck

The synthesis of 2,3,6-trisubstituted 1-oxo-1,2-dihydroisoquinolines as potent CRTh

Merck

Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides.

Merck

Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

Merck

Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.

Merck

Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol.

Merck

Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.

Merck

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.

Merck

Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.

Merck

Development of a prodrug of hydantoin based TACE inhibitor.

Merck

Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.

Merck

The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.

Merck

Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.

Merck

Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.

Merck

Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.

Merck

Recent progress towards clinically relevant ATP-competitive Akt inhibitors.

Merck

Benzoxazolinone aryl sulfonamides as potent, selective Na

Merck

Design, synthesis and SAR of substituted indoles as selective TrkA inhibitors.

Merck

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.

Merck

Affinity Selection-Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor.

Merck